Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eee3558418d62167856033c102e5d895 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_015b06914223e1628bc6a0b3d09dcde5 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-90 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate |
2020-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_805418bf5e3768d374233678dc1e3eb1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1bdfdbdfa5786a8ceeb5337569c29f75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05d96ad46de050cc6759871ea13808af http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c825944c320d0c162b5e69d3b10beb96 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_925322db44bd2233df387d70edb15748 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e248a0daaeb813d5ec3ccfba868c418 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c21432844f8bbc4f9ff4332dcc98de88 |
publicationDate |
2022-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CN-115151309-A |
titleOfInvention |
Anti-CLEC-1A antibody and its antigen-binding fragment |
abstract |
The present invention relates to the field of immunotherapy. The present invention provides novel specific anti-CLEC-1A compounds, especially antibodies. The compounds of the present invention can specifically bind to the CLEC-1A receptor and antagonize the binding of CLEC-1A to its endogenous ligand. The use of the compounds of the present invention is useful in the treatment of deleterious conditions. |
priorityDate |
2019-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |